Multiparametric Magnetic Resonance Imaging (mpMRI) Versus Prostate-Specific Membrane Antigen Positron Emission Tomography (PSMA-PET) for Detecting Clinically Significant Prostate Cancer in Transition Zone Lesions /PRostate Imaging With MRI and PET in the Transition Zone (PRIME-TZ)
Candidates for prostate biopsy with a PI-RADS ≥4 lesion located in the - transition zone of the prostate identified on mpMRI.
Ability and willingness to provide written informed consent.
You may not be if
Previous treatment for prostate cancer, including surgery, radiotherapy, or hormonal therapy.
Concomitant conditions that preclude or substantially interfere with imaging evaluation, including severe renal impairment, untreated severe claustrophobia, or mpMRI-incompatible metallic implants.
Contraindication to mpMRI or PSMA-PET, including severe renal impairment, MRI-incompatible implants, severe untreated claustrophobia, or known hypersensitivity to gadolinium-based contrast agents or the PSMA radiotracer.
Patients undergoing active surveillance without an immediate indication for prostate biopsy.
Clareo Health | Multiparametric Magnetic Resonance Imaging (mpMRI) Versus Prostate-Specific Membrane Antigen Positron Emission Tomography (PSMA-PET) for Detecting Clinically Significant Prostate Cancer in Transition Zone Lesions /PRostate Imaging With MRI and PET in the Transition Zone (PRIME-TZ)
